Side by side

David Evendon-Challis and Dr John Creek on why collaboration will be key in developing credible microbiome solutions
Transforming the landscape

How big tech and big pharma partnerships are providing deeper insights and improving patient outcomes
In the shadows

The pharma industry may just have more unsung heroes than any other.

News

View all

CR UK research backs liquid biopsy for breast cancer

Blood tests can provide a bigger, faster picture of mutations present within multiple tumours, the researchers say

13th December 2019

UK researchers make new Alzheimer’s disease discovery

Scientists hope the discovery will lead to new treatments for the disease

13th December 2019

Novartis’ Kisquali bests AZ’ Faslodex in breast cancer trial

Adding Kisquali to Faslodex resulted in an almost 30% reduction in risk of death compared to Faslodex alone

13th December 2019

EU approves new osteoporosis treatment

Amgen and UCB’s Evenity has been given the green light for postmenopausal women with severe osteoporosis to help prevent further fractures

13th December 2019

Boris Johnson remains UK prime minister

Conservatives win a huge majority after a crushing defeat for Labour

13th December 2019

Web Exclusives

View all

Labour's policy for the pharma industry

The Labour Party’s election manifesto presents something of a mixed bag for pharmaceutical companies, say Gareth Morgan and Aisling O’Dwyer

SmartPeople: David Logue

PharmaTimes talks to David Logue, senior vice president of commercial strategy at Veeva

Can private GP services benefit patients who can’t afford them?

Jessica Foreman looks at arguments for and against private GP services

Prepare to engage

After the election, Brexit will finally become real. Pharma must be ready to engage or risks being left behind.

Magazine

View more from the latest edition

Smart People: Hilary Hutton-Squire

PharmaTimes talks to Hilary Hutton-Squire, vice president and general manager of Gilead Sciences in the UK and Ireland, about the importance of valuing medicines in the right way

A clearer picture

Marni Hall and Nicola Stanislaus look at the growing role of real-world evidence

Raising the bar

A 2019 review has shown that the current system for detecting cancer is failing to reach its potential. Fujifilm’s Adrian Waller says we need a more tech-enabled and patient-centred approach

The year of no Brexit (again)

Political uncertainty became endemic during 2019, despite a lot of government planning

2019 – the return of the mega deal?

Globally mega deals continue to abound, domestically the mid-market and PE have been the core drivers of activity

Unlocking value

How can 2020 be the year that R&D really delivers value, people get real about data, and pharma starts to develop even better medicines?

For decades intrepid pharma sales forces navigated the road network of Great Britain with little more than paper, pen and personality – hoping that one day the tools of their trade would mirror the cutting-edge science of the products they showcased. In recent years, the digital era has truly arrived, but as 2020 looms, big challenges still remain